Evidence map›Paper›PMID 35858989›Full record

ArticleMolecular psychiatry2022

Deep brain stimulation of the nucleus accumbens in the treatment of severe alcohol use disorder: a phase I pilot trial.

Benjamin Davidson, Peter Giacobbe, Tony P George, Sean M Nestor, Jennifer S Rabin, Maged Goubran, Alexander J Nyman, Anusha Baskaran, Ying Meng, Christopher B Pople and 4 more

2 registry-linked trialsAbstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Molecular psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03660124 naunknown statusnot on this map

Deep Brain Stimulation (DBS) for the Treatment of Refractory Alcohol Use Disorder (AUD): Pilot Trial

TypeinterventionalSponsorSunnybrook Health Sciences CentreRan2018 to 2024Enrolled10ConditionsAlcohol Use DisorderArmsDeep Brain Stimulation
NCT07341230 narecruitingnot on this mapstarted 2025, after this paper: background citation

Deep Brain Stimulation for Disorders of Addiction: Mechanisms and a Pilot Blinded Randomized Cross-over Placebo Controlled Trial

TypeinterventionalSponsorUniversity of CambridgeRan2025 to 2027Enrolled9ConditionsAlcohol Use DisorderArmsDual-Target Deep Brain Stimulation, Nucleus Accumbens Deep Brain Stimulation, Ventral Internal Capsule Deep Brain Stimulation, Sham Deep Brain Stimulation
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. A systematic review and meta-analysis of neuromodulation therapies for substance use disorders.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Change in brain molecular landscapes following electrical stimulation of the nucleus accumbens.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. The brain's action-mode network.Nature reviews. Neuroscience · 2025
    Review
  18. Modulation of Alcohol Use Disorder by Brain Stimulation.Current topics in behavioral neurosciences · 2025
    Review
  19. Review
  20. Deep brain stimulation for psychostimulant use disorders.Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Benjamin DavidsonDivision of Neurosurgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. benjamin.davidson@mail.utoronto.ca.ORCID http://orcid.org/0000-0001-5264-1190
Peter GiacobbeHarquail Centre for Neuromodulation, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada.
Tony P GeorgeAddictions Division, Centre for Complex Interventions, Temerty Centre for Therapeutic Brain Interventions, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada.ORCID http://orcid.org/0000-0003-1645-9767
Sean M NestorHarquail Centre for Neuromodulation, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada.
Jennifer S RabinHarquail Centre for Neuromodulation, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada.ORCID http://orcid.org/0000-0003-4754-2221
Maged GoubranHarquail Centre for Neuromodulation, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada.ORCID http://orcid.org/0000-0001-5880-0818
Alexander J NymanHarquail Centre for Neuromodulation, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada.
Anusha BaskaranHarquail Centre for Neuromodulation, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada.
Ying MengDivision of Neurosurgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
Christopher B PopleHarquail Centre for Neuromodulation, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada.
Simon J GrahamDepartment of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Fred TamPhysical Sciences Platform, Sunnybrook Research Institute, Toronto, ON, Canada.
Clement HamaniDivision of Neurosurgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-7586-2487
Nir LipsmanDivision of Neurosurgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. nir.lipsman@sunnybrook.ca.ORCID http://orcid.org/0000-0002-4820-3056
Sunnybrook Health Science Centre · CACentre for Addiction and Mental Health · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alcohol use disorder (AUD) is a highly prevalent, often refractory, medical illness. The symptoms of AUD are driven by dysfunction in several neurocircuits centered on the nucleus accumbens (NAc). Case reports and animal studies suggest NAc-DBS may be an effective harm-reduction treatment in severe AUD. Six patients with severe, refractory AUD underwent NAc-DBS. Safety metrics and clinical outcomes were recorded. Positron emission tomography (FDG-PET) was used to measure glucose metabolism in the NAc at baseline and 6 months. Functional magnetic resonance imaging (fMRI) was used to characterize postoperative changes in NAc functional connectivity to the rest of the brain, as well as NAc and dorsal striatal reactivity to alcoholic visual cues. This study was registered with ClinicalTrials.gov, NCT03660124. All patients experienced a reduction in craving. There was a significant reduction in alcohol consumption, alcohol-related compulsivity, and anxiety at 12 months. There was no significant change in depression. FDG-PET analysis demonstrated reduced NAc metabolism by 6 months, which correlated with improvements in compulsive drinking behaviors. Clinical improvement correlated with reduced functional connectivity between the NAc and the visual association cortex. Active DBS was associated with reduced activation of the dorsal striatum during passive viewing of alcohol-containing pictures. NAc-DBS is feasible and safe in patients with severe, otherwise refractory AUD. It is associated with a reduction in cravings and addictive behavior. A potential mechanism underlying this process is a down-regulation of the NAc, a disruption of its functional connectivity to the visual association cortex, and interference of cue-elicited dorsal striatum reactivity. Trial Registration NCT03660124 ( www.clinicaltrials.gov ).

Indexed as

AlcoholismDeep Brain StimulationFluorodeoxyglucose F18HumansNucleus AccumbensPilot ProjectsFluorodeoxyglucose F18

Identifiers

PMID35858989
OpenAlexW4286111422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.